Pharm Biol
December 2024
Context: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance.
© LitMetric 2025. All rights reserved.